Gitnux/Report 2026

AI Second Opinion Industry Statistics

The AI second opinion market is moving into clinical adoption in 2026, with 81% of physicians reporting awareness or use of AI in practice, and you can compare companies and trends around that shift.
7Statistics
19Sources
1Sections
12mRead
AI Second Opinion Industry Statistics
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The AI second opinion industry at a glance

The AI second opinion industry is moving from experimentation toward clinical adoption: 81% of physicians reported awareness or use of AI in practice in 2026, although regulation, validation and liability remain significant constraints.

81%[5]
Physicians using or aware of AI, 2026
72%[5]
Physicians incorporating AI use cases, 2026
1,600+[6]
FDA-authorized AI medical devices, 2026
54%[7]
AI-enabled share of digital-health funding, 2025
Segmentation
AI second-opinion use is concentrated in decision-support and information-intensive workflows. In the AMA’s 2026 physician survey, 39% of physicians reported using AI to summarize medical research and standards of care, 17% reported assistive-diagnosis use, and nearly half strongly opposed patients using AI to interpret radiology or pathology results.[5]
Key players & concentration
The market remains fragmented across clinical-information platforms, diagnostic-device vendors, telehealth providers and digital-health companies; no reliable public source identified a defensible concentration ratio for AI second-opinion providers. Funding is nevertheless concentrating around AI-enabled companies: they captured 54% of U.S. digital-health funding in 2025.[7]
Trends, drivers & challenges
Adoption is being driven by perceived gains in diagnostic accuracy, clinical efficiency and access to medical knowledge. The AMA reported that 76% of physicians believe AI provides an advantage in caring for patients, while 88% identified safety and efficacy validation as important for broader adoption and 86% cited data privacy concerns.[5]
Consumer behavior & competition
Physicians are increasingly using AI as an assistive layer rather than a replacement for clinical judgment: 39% use it to summarize research and standards of care, while 17% use it for assistive diagnosis. Patient-facing competition is constrained by clinician skepticism, with nearly half of surveyed physicians strongly opposing patient use of AI to interpret radiology or pathology results.[5]
Regulation
In the United States, AI-enabled medical devices are regulated by the FDA through premarket pathways including 510(k), De Novo classification and premarket approval. The FDA reported more than 1,600 authorized AI-enabled medical devices as of September 2026 and issued draft lifecycle guidance for developers in January 2025.[6]
Latest news
The latest adoption data point to rapid mainstreaming among clinicians: the AMA’s 2026 survey found that 81% of physicians reported awareness or use of AI in practice, up from 66% in 2024 and 38% in 2023. AI-enabled digital-health companies also captured 54% of total U.S. digital-health funding in 2025.[5][7]

02 Ranking

Top 10 Companies in the AI Second Opinion Industry

The leading companies in the AI second opinion industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Ada Health stands out for AI symptom assessment because it reports an AI assessment of 3,000+ conditions for over 50 million users, while Ubie focuses on AI symptom checking since it reports more than 50 million cumulative patient users for its AI symptom checker.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in AI symptom assessment

    Ada Health

    DE

    Ranked #1 · 9.7 · AI symptom assessment

    Why we picked it: It supports AI symptom assessment and care navigation at scale across its large user base.

  2. Leader in AI-assisted remote second opinions

    Cleveland Clinic

    US

    Ranked #3 · 8.9 · AI-assisted remote second opinions

    Why we picked it: It provides AI-assisted remote second opinions through AI triage and case analysis within its MyConsult offering.

  3. Leader in AI-enabled second opinions

    Nano-X Imaging

    IL

    Ranked #5 · 8.5 · AI-enabled second opinions

    Why we picked it: It added AI functionality to its Second Opinions online medical consultation service for radiology-linked use.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the AI second opinion industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Ada Health

AI symptom assessment · DE

9.7
2

Ubie

AI symptom assessment · JP

8.9
3

Cleveland Clinic

AI-assisted remote second opinions · US

8.9
4

Partners HealthCare

AI-assisted remote second opinions · US

8.9
5

Nano-X Imaging

AI-enabled second opinions · IL

8.5
6

Teladoc Health

AI-powered virtual second opinion services, global · US

8.4
7

SCOR

Vitaex AI underwriting second opinions for insurance, global · FR

8.2
8

Infermedica

AI symptom assessment, triage and care routing · PL

8.0
9

WorldCare International

AI-enabled medical second opinion concierge, global · US

8.0
10

TCE Group

AI-supported global medical second opinions · CA

8.0

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 10 companies in the AI second opinion industry. In AI Second Opinion Industry Statistics. Gitnux. https://gitnux.org/ai-second-opinion-industry-statistics/#top-companies

04 Statistics

Market Intelligence

Market size figures in the medical second-opinion parent category show scale from $5.33 billion in 2023 to $5.726 billion in 2024. A 2031 projection reaches $31.25 billion from $9.85 billion in 2024, covering AI-enabled platforms within broader services.

Market size and revenue in the AI second opinion industry

  • $5.33 billion was the global 2023 market size for medical second-opinion services, including hospitals, health insurers and online services; this broader parent category contains AI second-opinion software but is not software-only.[1]
  • $5.726 billion was the global 2024 medical second-opinion market value, covering the broader service market rather than AI software alone; AI-enabled second-opinion platforms are included only as part of that parent category.[2]
  • $8.40 billion was the global 2023 market size for medical second-opinion services, a broader parent category that includes online services, physicians, hospitals, insurers and specialty clinics rather than AI software alone.[3]
  • $6.00 billion was the estimated global 2024 medical second-opinion market size, covering remote, in-person and hybrid services across 17 countries; the estimate is a broader parent-category proxy for AI second-opinion software.[4]

Growth forecasts for the AI second opinion industry

  • The global medical second-opinion services market is projected to reach $31.25 billion in 2031 from $9.85 billion in 2024, a 17.93% CAGR; this broader parent category includes AI-enabled platforms but is not software-only.[3]
  • The global medical second-opinion services market is projected to reach $15.40 billion in 2031 from $5.33 billion in 2023, a 14.2% CAGR; this broader parent category includes online services and AI-enabled platforms.[1]
  • The global medical second-opinion services market is projected to reach $12.5 billion in 2030 from an estimated $6.41 billion in 2025, a 6.41% CAGR; this is a broader parent-category forecast, not an AI-software-only forecast.[4]

Key questions about the AI second opinion industry

What was the global market size for medical second-opinion services in 2024?
The global medical second-opinion market was $5.726 billion in 2024. That value covers the broader service market rather than AI software alone.
How fast is the broader medical second-opinion services market growing to 2031?
The global medical second-opinion services market is projected to reach $31.25 billion in 2031 from $9.85 billion in 2024, a 17.93% CAGR. This includes online services and AI-enabled platforms.
Which companies lead the AI second opinion industry?
Ada Health stands out for AI symptom assessment because it reports an AI assessment of 3,000+ conditions for over 50 million users, while Ubie focuses on AI symptom checking since it reports more than 50 million cumulative patient users for its AI symptom checker.
What technology shift is showing up most in physician-reported use in 2026?
In the AMA’s 2026 physician survey, 39% reported using AI to summarize medical research and standards of care and 17% reported assistive-diagnosis use. Nearly half strongly opposed patients using AI to interpret radiology or pathology results.
How is competition structured across the AI second opinion market?
The market remains fragmented across clinical-information platforms, diagnostic-device vendors, telehealth providers and digital-health companies. No reliable public source identified a defensible concentration ratio for AI second-opinion providers.
What regulatory supply exists for AI medical devices in the U.S. as of September 2026?
The FDA reported more than 1,600 authorized AI-enabled medical devices as of September 2026. It also issued draft lifecycle guidance for developers in January 2025.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). AI Second Opinion Industry Statistics. Gitnux. https://gitnux.org/ai-second-opinion-industry-statistics
MLA
Samuel Norberg. "AI Second Opinion Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/ai-second-opinion-industry-statistics.
Chicago
Samuel Norberg. 2026. "AI Second Opinion Industry Statistics." Gitnux. https://gitnux.org/ai-second-opinion-industry-statistics.